NDA 018998 · Bausch
Vasotec
Enalapril Maleate · Oral
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Aug 1, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1985
Dec 24, 1985
Approved uses
6
Original approval plus efficacy supplements
Registered trials
156
43 Phase 3, 13 recruiting
FAERS reports
24,669
19,955 serious, 2,779 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning. • When pregnancy is detected, discontinue VASOTEC ® as soon as possible. • Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus (see WARNINGS, Fetal Toxicity ).
What it is approved for
From the label in effect Jan 23, 2026.
INDICATIONS AND USAGE Hypertension VASOTEC is indicated for the treatment of hypertension. VASOTEC is effective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of VASOTEC and thiazides are approximately additive. Heart Failure VASOTEC is indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. In these patients VASOTEC improves symptoms, increases survival, and decreases the frequency of hospitalization (see CLINICAL PHARMACOLOGY , Heart Failure , Mortality Trials for details and limitations of survival trials). Asymptomatic Left Ventricular Dysfunction In clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), VASOTEC decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure (see CLINICAL PHARMACOLOGY , Heart Failure , Mortality Trials for details and limitations of survival trials). In using VASOTEC consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that VASOTEC does not have a similar risk (see WARNINGS , Neutropenia/Agranulocytosis ). In considering use of VASOTEC, it should be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, it should be noted that black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks (see WARNINGS , Head and...
Mechanism: Mechanism of Action Enalapril, after hydrolysis to enalaprilat, inhibits angiotensin-converting enzyme (ACE) in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex. The beneficial effects of enalapril in hypertension and heart failure appear to result primarily from suppression of the renin-angiotensin-aldosterone system. Inhibition of ACE results in decreased plasma angiotensin II, which leads to decreased...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 13, 2001 Supplement 59 · Efficacy ReviewLetterLabel
- Nov 4, 1993 Supplement 32 · Efficacy
- Apr 8, 1992 Supplement 27 · Efficacy
- Jun 12, 1990 Supplement 22 · Efficacy Review
- Jun 24, 1988 Supplement 7 · Efficacy
- Dec 24, 1985 Original approval · Type 1 - New Molecular Entity · priority review Other Important Information from FDAReview
4 products under this application
- VASOTEC · ENALAPRIL MALEATE 2.5MG · TABLET, ORAL · Prescription · TE AB
- VASOTEC · ENALAPRIL MALEATE 20MG · TABLET, ORAL · Prescription · TE AB
- VASOTEC · ENALAPRIL MALEATE 5MG · TABLET, ORAL · Prescription · TE AB
- VASOTEC · ENALAPRIL MALEATE 10MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Enalapril" as an intervention, any sponsor and status, largest first.
- Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk AssessmentPivotal-lookingCompleted
University of VigoAcademic, hospital or other
NCT00741585 · 21,983 participants · Start Sep 1, 2008 · Primary completion Jun 30, 2018
Drug: Any antihypertensive medication alone or in combination; Any antihypertensive medication alone or in combination · For: Essential Hypertension; Cardiovascular Disease; Stroke and 1 more
Sites: Friol, Spain; A Estrada, Spain; Baiona, Spain · 20 sites in all
- China Stroke Primary Prevention TrialPivotal-lookingCompleted
Shenzhen Ausa Pharmed Co.,LtdIndustry
NCT00794885 · 20,702 participants · Start May 2008 · Primary completion Aug 2013
Drug: Enalapril/folic acid; Enalapril maleate · For: Primary Hypertension
Sites: Anqing, China; Lianyungang, China
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaPivotal-lookingRecruiting
UMC UtrechtAcademic, hospital or other
NCT02735707 · 20,000 participants (planned) · Start Apr 11, 2016 · Primary completion Jun 2028
Drug: Ceftriaxone + Macrolide; Moxifloxacin or Levofloxacin and 47 more · For: Respiratory Tract Diseases; Influenza (Pandemic); Influenza and 7 more
Sites: Jacksonville, Florida; Augusta, Georgia; Chicago, Illinois · 408 sites in all
- Primary Prevention of Cardiovascular Disease (CVD) in Pre-diabetic & Pre-hypertensive SubjectsPivotal-lookingStatus unknown
Ramathibodi HospitalAcademic, hospital or other
NCT01364675 · 8,900 participants (planned) · Start Jan 2012 · Primary completion Jul 2016
Drug: Metformin+Enalapril+Simvastatin; Placebo tablet · For: Pre-diabetes; Pre-hypertension
Sites: Muang District, Thailand
- This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart FailurePivotal-lookingTerminated
Novartis PharmaceuticalsNovartis (NVS)
NCT01035255 · 8,442 participants · Start Dec 2009 · Primary completion May 2014
Drug: LCZ696 200 mg BID; Enalapril 10 mg BID · For: Heart Failure With Reduced Ejection Fraction
Sites: Birmingham, Alabama; Huntsville, Alabama; Mobile, Alabama · 1,031 sites in all
- Prevention of Cardiovascular Disease in Middle-aged and Elderly Iranians Using a Single PolyPillPivotal-lookingCompleted
Tehran University of Medical SciencesAcademic, hospital or other
NCT01271985 · 8,410 participants · Start Feb 2011 · Primary completion Jan 2019
Drug: PolyPill · For: Cardiovascular Diseases
Sites: Gonbad, Iran
- Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart FailurePivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT00853658 · 7,064 participants · Start Mar 2009 · Primary completion Oct 2015
Drug: Enalapril; Aliskiren · For: Chronic Heart Failure
Sites: Huntsville, Alabama; Mobile, Alabama; Tucson, Arizona · 806 sites in all
- Systolic Hypertension in Europe Placebo-Controlled TrialPivotal-lookingTerminated
KU LeuvenAcademic, hospital or other
NCT02088450 · 4,695 participants · Start Feb 1990 · Primary completion Feb 1997
Drug: Active treatment with nitrendipine (10-40 mg/day). · For: Isolated Systolic Hypertension
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- nausea1,385
- dyspnoea1,286
- diarrhoea1,275
- fatigue1,141
- dizziness1,107
- drug ineffective1,010
- pain954
- vomiting929
- asthenia897
- hypertension889
- headache877
- drug interaction848
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1,375 |
| 2005 | 1,306 |
| 2006 | 1,534 |
| 2007 | 1,346 |
| 2008 | 1,745 |
| 2009 | 1,585 |
| 2010 | 1,975 |
| 2011 | 2,502 |
| 2012 | 2,006 |
| 2013 | 564 |
| 2014 | 1,001 |
| 2015 | 785 |
| 2016 | 786 |
| 2017 | 785 |
| 2018 | 815 |
| 2019 | 761 |
| 2020 | 643 |
| 2021 | 625 |
| 2022 | 604 |
| 2023 | 585 |
| 2024 | 564 |
| 2025 | 447 |
| 2026 | 327 |
Recalls
1 FDA enforcement reports for this application.
May 21, 2014 · Class III · Terminated
Labeling: Incorrect or Missing Package Insert: Product is packaged with the incorrect version of the package insert.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Vasotec (Enalapril Maleate)
2024 spending
$3.3M
Beneficiaries
265
1,253 claims
Per beneficiary
$12,335
$24.97 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $4,856,329 |
| 2021 | $4,109,497 |
| 2022 | $3,579,427 |
| 2023 | $3,361,199 |
| 2024 | $3,268,686 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Angiotensin-neprilysin inhibition versus enalapril in heart failure.
McMurray JJ, Packer M, Desai AS, et al. · N Engl J Med 2014 · Comparative Study, Multicenter Study
- Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure.
Velazquez EJ, Morrow DA, DeVore AD, et al. · N Engl J Med 2019 · Multicenter Study, Randomized Controlled Trial
- Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).
· N Engl J Med 1987 · Clinical Trial, Randomized Controlled Trial
- Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial.
Huo Y, Li J, Qin X, et al. · JAMA 2015 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Renal protective effect of enalapril in diabetic nephropathy.
Björck S, Mulec H, Johnsen SA, et al. · BMJ 1992 · Clinical Trial, Randomized Controlled Trial
- Estimated Stroke-Free Survival of Folic Acid Therapy for Hypertensive Adults: Projection Based on the CSPPT.
Zhang T, Lin T, Wang Y, et al. · Hypertension 2020 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
Sponsor: Bausch
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.